Ontology highlight
ABSTRACT:
SUBMITTER: Klei HE
PROVIDER: S-EPMC1951392 | biostudies-literature | 2007 Sep
REPOSITORIES: biostudies-literature
Klei Herbert E HE Kish Kevin K Lin Pin-Fang M PF Guo Qi Q Friborg Jacques J Rose Ronald E RE Zhang Yaqun Y Goldfarb Valentina V Langley David R DR Wittekind Michael M Sheriff Steven S
Journal of virology 20070530 17
Atazanavir, which is marketed as REYATAZ, is the first human immunodeficiency virus type 1 (HIV-1) protease inhibitor approved for once-daily administration. As previously reported, atazanavir offers improved inhibitory profiles against several common variants of HIV-1 protease over those of the other peptidomimetic inhibitors currently on the market. This work describes the X-ray crystal structures of complexes of atazanavir with two HIV-1 protease variants, namely, (i) an enzyme optimized for ...[more]